MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PATERSON, A. R. P.
Right arrow Articles by CASS, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PATERSON, A. R. P.
Right arrow Articles by CASS, C. E.

Molecular Pharmacology, Vol 18, 40-44, Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics

A Common Basis for Inhibition of Nucleoside Transport by Dipyridamole and Nitrobenzylthioinosine?

ALAN R. P. PATERSON 1, EDA Y. LAU 1, EWA DAHLIG 1, and CAROL E. CASS 1

1 Cancer Research Unit (McEachern Laboratory) and Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada

Transport of uridine by monolayer cultures of HeLa cells was inhibited by nitrobenzylthioinosine, dipyridamole, and lidoflazine. Biphasic concentration-effect curves were obtained for inhibition of nucleoside transport by nitrobenzylthioinosine, but not for inhibition by dipyridamole. Dipyridamole and lidoflazine interfered with high-affinity binding of [3H]nitrobenzylthioinosine to HeLa cells in an apparently competitive fashion; values of 1, 30, and 300 nM were obtained for dissociation constants, respectively, for nitrobenzylthioinosine, dipyridamole, and lidoflazine. The apparent competition with nitrobenzylthioinosine at the latter’s high-affinity binding sites suggests that dipyridamole and lidoflazine inhibit nucleoside transport by interaction with these sites.

Submitted on September 17, 1979
Accepted on January 21, 1980




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
F. Visser, J. Zhang, R. T. Raborn, S. A. Baldwin, J. D. Young, and C. E. Cass
Residue 33 of Human Equilibrative Nucleoside Transporter 2 Is a Functionally Important Component of Both the Dipyridamole and Nucleoside Binding Sites
Mol. Pharmacol., April 1, 2005; 67(4): 1291 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Visser, S. A. Baldwin, R. E. Isaac, J. D. Young, and C. E. Cass
Identification and Mutational Analysis of Amino Acid Residues Involved in Dipyridamole Interactions with Human and Caenorhabditis elegans Equilibrative Nucleoside Transporters
J. Biol. Chem., March 25, 2005; 280(12): 11025 - 11034.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Visser, M. F. Vickers, A. M. L. Ng, S. A. Baldwin, J. D. Young, and C. E. Cass
Mutation of Residue 33 of Human Equilibrative Nucleoside Transporters 1 and 2 Alters Sensitivity to Inhibition of Transport by Dilazep and Dipyridamole
J. Biol. Chem., January 4, 2002; 277(1): 395 - 401.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
R. B. Tenser, A. Gaydos, and K. A. Hay
Inhibition of Herpes Simplex Virus Reactivation by Dipyridamole
Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3657 - 3659.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. R. Crawford, D. H. Patel, C. Naeve, and J. A. Belt
Cloning of the Human Equilibrative, Nitrobenzylmercaptopurine Riboside (NBMPR)-insensitive Nucleoside Transporter ei by Functional Expression in a Transport-deficient Cell Line
J. Biol. Chem., February 27, 1998; 273(9): 5288 - 5293.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics